Latest Period
Q4 2025
Security Snapshot
Dyne Therapeutics, Inc. - COMMON STOCK (DYN) Institutional Ownership
CUSIP: 26818M108
13F Institutional Holders and Ownership History from Q3 2020 to Q1 2026
Institutions Reporting
230
Shares (Excl. Options)
177,888,919
Price
$19.56
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / COMMON STOCK
- Symbol
- DYN on Nasdaq
- Shares outstanding
- 164,981,109
- Price per share
- $18.10
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 177,888,919
- Total reported value
- $3,479,390,610
- % of total 13F portfolios
- 0.01%
- Share change
- +22,989,320
- Value change
- +$511,413,657
- Number of holders
- 230
- Price from insider filings
- $18.10
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- DYN - Dyne Therapeutics, Inc. - COMMON STOCK is tracked under CUSIP 26818M108.
- 230 institutions reported positions in Q4 2025.
- 8 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 230 to 76 between Q4 2025 and Q1 2026.
- Reported value moved from $3,479,390,610 to $336,224,315.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 230 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 26818M108?
CUSIP 26818M108 identifies DYN - Dyne Therapeutics, Inc. - COMMON STOCK in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 26818M108:
Significant Owners of Dyne Therapeutics, Inc. - COMMON STOCK (DYN) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 16% | +50% | $425,254,992 | +$144,613,568 | 26,578,437 | +52% | T. Rowe Price Investment Management, Inc. | 28 Feb 2026 |
| JANUS HENDERSON GROUP PLC | 8.5% | -19% | $251,645,523 | -$15,543,028 | 13,887,722 | -5.8% | JANUS HENDERSON GROUP PLC | 31 Dec 2025 |
| FMR LLC | 5.4% | +16% | $161,252,536 | +$67,217,717 | 8,908,980 | +71% | FMR LLC | 31 Mar 2026 |
| BlackRock, Inc. | 5.8% | $73,080,236 | 6,577,879 | BlackRock, Inc. | 31 Mar 2025 | |||
| Atlas Venture Fund XI, L.P. | 4% | $72,275,396 | 5,713,470 | Atlas Venture Associates XI, L.P. | 30 Sep 2025 | |||
| Forbion Capital Fund IV Cooperatief U.A. | 4.8% | $60,000,055 | 5,400,545 | ForDyne B.V. | 31 Mar 2025 | |||
| RTW INVESTMENTS, LP | 1.5% | -72% | $18,782,199 | -$39,196,902 | 1,690,567 | -68% | RTW Investments, LP | 31 Mar 2025 |
| Point72 Asset Management, L.P. | 1.5% | -72% | $18,546,390 | -$39,187,803 | 1,669,342 | -68% | Point72 Asset Management, L.P. | 31 Mar 2025 |
As of 31 Dec 2025, 230 institutional investors reported holding 177,888,919 shares of Dyne Therapeutics, Inc. - COMMON STOCK (DYN). This represents 108% of the company’s total 164,981,109 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Dyne Therapeutics, Inc. - COMMON STOCK (DYN) together control 82% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 11% | 17,540,089 | +524% | 0.22% | $343,085,000 |
| JANUS HENDERSON GROUP PLC | 8.4% | 13,887,722 | -5.8% | 0.12% | $271,603,659 |
| VANGUARD GROUP INC | 6.8% | 11,215,565 | +15% | 0% | $219,376,451 |
| BlackRock, Inc. | 6.8% | 11,190,838 | +16% | 0% | $218,892,793 |
| Atlas Venture Life Science Advisors, LLC | 5.5% | 9,130,465 | 0% | 21% | $178,591,895 |
| STATE STREET CORP | 4.1% | 6,692,745 | +27% | 0% | $130,910,092 |
| FMR LLC | 4% | 6,569,921 | +22% | 0.01% | $128,507,653 |
| FCPM III SERVICES B.V. | 3.3% | 5,462,846 | 0% | 14% | $106,853,268 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 3.1% | 5,172,000 | +46% | 0.15% | $101,164,320 |
| Orbis Allan Gray Ltd | 2.9% | 4,801,928 | 0.39% | $93,925,712 | |
| TCG Crossover Management, LLC | 2.8% | 4,615,144 | 0% | 3% | $90,272,217 |
| JPMORGAN CHASE & CO | 2.2% | 3,549,909 | +5.5% | 0% | $69,436,220 |
| Siren, L.L.C. | 2.1% | 3,502,941 | -26% | 2% | $68,517,526 |
| PERCEPTIVE ADVISORS LLC | 2.1% | 3,478,944 | +544% | 1.2% | $68,048,145 |
| GEODE CAPITAL MANAGEMENT, LLC | 2% | 3,263,429 | +14% | 0% | $63,844,380 |
| ARMISTICE CAPITAL, LLC | 2% | 3,249,708 | +6.1% | 1.6% | $63,564,288 |
| Frazier Life Sciences Management, L.P. | 1.9% | 3,153,082 | +16% | 1.7% | $61,674,284 |
| Deep Track Capital, LP | 1.6% | 2,650,000 | +32% | 1.2% | $51,834,000 |
| Vivo Capital, LLC | 1.6% | 2,614,960 | 0% | 3.3% | $51,148,618 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.4% | 2,323,789 | +66% | 0% | $45,454,000 |
| GOLDMAN SACHS GROUP INC | 1.4% | 2,283,191 | +20% | 0.01% | $44,659,216 |
| Sofinnova Investments, Inc. | 1.4% | 2,254,161 | +129% | 1.9% | $44,091,389 |
| ORBIMED ADVISORS LLC | 1.3% | 2,202,184 | -4.8% | 0.92% | $43,074,719 |
| VR ADVISER, LLC | 1.3% | 2,173,913 | 0% | 2.1% | $42,521,738 |
| FRANKLIN RESOURCES INC | 1.2% | 2,006,638 | +43% | 0.01% | $39,249,837 |
Institutional Holders of Dyne Therapeutics, Inc. - COMMON STOCK (DYN) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 18,545,495 | $336,224,315 | -$2,648,513 | $18.13 | 76 |
| 2025 Q4 | 177,888,919 | $3,479,390,610 | +$511,413,657 | $19.56 | 230 |
| 2025 Q3 | 155,774,921 | $1,970,440,035 | +$381,733,004 | $12.65 | 205 |
| 2025 Q2 | 128,553,808 | $1,223,875,095 | +$58,226,785 | $9.52 | 195 |
| 2025 Q1 | 121,788,688 | $1,284,331,056 | -$75,923,327 | $10.46 | 202 |
| 2024 Q4 | 111,635,776 | $2,630,327,572 | -$39,471,758 | $23.56 | 199 |
| 2024 Q3 | 112,428,939 | $4,033,469,001 | -$6,349 | $35.92 | 200 |
| 2024 Q2 | 110,972,098 | $3,915,861,443 | +$555,159,053 | $35.29 | 191 |
| 2024 Q1 | 95,365,001 | $2,707,385,907 | +$786,881,972 | $28.39 | 167 |
| 2023 Q4 | 69,922,072 | $929,957,219 | +$57,596,260 | $13.30 | 123 |
| 2023 Q3 | 59,888,832 | $536,594,556 | +$1,685,315 | $8.96 | 114 |
| 2023 Q2 | 59,189,838 | $665,851,766 | +$50,911,029 | $11.25 | 117 |
| 2023 Q1 | 54,627,733 | $628,721,822 | +$56,536,368 | $11.52 | 125 |
| 2022 Q4 | 49,732,095 | $576,377,450 | +$50,130,248 | $11.59 | 112 |
| 2022 Q3 | 44,533,854 | $565,571,380 | -$9,010,573 | $12.70 | 100 |
| 2022 Q2 | 46,679,856 | $320,706,640 | -$8,056,035 | $6.87 | 87 |
| 2022 Q1 | 47,256,134 | $455,432,690 | -$4,233,139 | $9.64 | 90 |
| 2021 Q4 | 47,794,946 | $568,260,037 | +$18,929,604 | $11.89 | 90 |
| 2021 Q3 | 32,306,202 | $524,727,164 | -$16,367,213 | $16.24 | 80 |
| 2021 Q2 | 35,805,078 | $753,366,735 | +$36,093,361 | $21.04 | 75 |
| 2021 Q1 | 31,379,394 | $487,292,000 | +$72,426,450 | $15.53 | 72 |
| 2020 Q4 | 26,339,155 | $552,433,805 | +$28,795,524 | $21.00 | 67 |
| 2020 Q3 | 24,527,914 | $493,744,000 | +$493,744,015 | $20.19 | 49 |